Biotech News
Jazz Pharmaceuticals Strikes Strategic $820M Research Deal with AbCellera for Next-Gen T-Cell Engaging Antibodies
Discover how Jazz Pharmaceuticals and AbCellera are joining forces in a high-stakes, $820M biopharma collaboration to pioneer next-generation T-cell engaging (TCE) multispecific antibodies targeting gastrointestinal cancers and challenging solid tumors.